1. Coronavirus Disease 2019 (COVID-19): A Brief Overview of Features and Current Treatment
- Author
-
Shereen M. Aleidi, Enas Al-Zayadneh, Montaha Al-Iede, Amirah Daher, Manar Al-lawama, Taima Khawaldeh, Eman F. Badran, and Basim Alqutawneh
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,ARDS ,Global Health ,medicine.disease_cause ,Antiviral Agents ,Asymptomatic ,law.invention ,Randomized controlled trial ,law ,Pandemic ,medicine ,Humans ,Intensive care medicine ,Aged ,Coronavirus ,business.industry ,Mortality rate ,COVID-19 ,Outbreak ,Middle Aged ,medicine.disease ,Pneumonia ,Female ,medicine.symptom ,business - Abstract
Since the report of the first cases of pneumonia caused by SARS-CoV-2 in December 2019, COVID-19 has become a pandemic and is globally overwhelming healthcare systems. The symptoms of COVID-19 vary from asymptomatic infection to severe complicated pneumonia with acute respiratory distress syndrome (ARDS) and multiple organ failure leading to death. The estimated case-fatality rate among infected patients in Wuhan, the city where the first case appeared, was 1.4%, with 5.1 times increase in the death rate among those aged above 59 years than those aged 30–59 years. In the absence of a proven effective and licensed treatment, many agents that showed activity against previous coronavirus outbreaks such as SARS and MERS have been used to treat SARS-CoV-2 infection. The SARS-CoV-2 is reported to be 80% homologous with SARS-CoV, and some enzymes are almost 90% homologous. Antiviral drugs are urgently required to reduce case fatality-rate and hospitalizations to relieve the burden on healthcare systems worldwide. Randomized controlled trials are ongoing to assess the efficacy and safety of several treatment regimens.
- Published
- 2021
- Full Text
- View/download PDF